Top Tweets for #FSP20
Hot off the press! 📰 The November Greenwall News features @HollyLynchez, @BlumenthalBarby, @jgreene2, @btuckeredmonds, @GovindPersad, @jasonkarlawish and more! Plus: our new grant initiative, the 2022 Stubing Lecture, and takeaways from our #FSP20 panel. https://t.co/hWKKlrVNun
Last week, The Greenwall Foundation celebrated the 20th year of the Faculty Scholars Program. Congratulations and thank you to the remarkable people that make this community special! #FSP20
“The Faculty Scholars Program has imprinted in Scholars the importance of giving back. It’s made a community of bioethics scholars...who support each other and influence the field of bioethics." #FSP20 https://t.co/MMCFD6Xtls
Last week, we hosted a panel discussion about the state of public trust in the FDA: Has it been lost? If so, why? And how might it be won back? Read more and watch that panel in its entirety here: https://t.co/e7yykGLksu #FSP20
📺 Watch LDI Senior Fellow Holly Fernandez Lynch (@HollyLynchez) of @PennMedicine and @pennlaw share insights at the FDA #FSP20 discussion. ⤵️
A question that frequently came up during today's FDA #FSP20 discussion:
How do we balance the speed of developing new drugs with the confidence of knowing they really work?
@HollyLynchez shares some more insights:
A question that frequently came up during today's FDA #FSP20 discussion:
How do we balance the speed of developing new drugs with the confidence of knowing they really work?
@HollyLynchez shares some more insights:
For more exciting conversations like today’s and the latest bioethics news and funding opportunities, sign up for our newsletter: https://t.co/bDYIT1HzAT #FSP20
Question about #lecanemab and @US_FDA consideration - @jasonkarlawish urges @US_FDA to clearly communicate reasons for their decision, what the type of approval means, and considerations that went into decisions. Lessons learned from #aducanemab #fsp20 #bioethics #dementia
In case you missed today’s webcast, we’ll be sharing the recording early next week on https://t.co/cAoUJhFK0W. Stay tuned! #FSP20
Thank you @adamfeuerstein, @jasonkarlawish, @akesselheim, @hollylynchez and @keithwailoo for a great panel on how we can work to restore trust in the FDA: an insightful, important, and timely conversation. #FSP20
There's a tension between what patients need today and what patients need in the future. Regulators like FDA have to always be looking at that bigger picture, shares @HollyLynchez #FSP20
Another, related, theme we're hearing: distrust or questioning of FDA often stems from lack of knowledge about the agency's existing structures, procedures. Examples: lack of understanding around "expedited approvals" and the structures in place to facilitate right to try. #FSP20
@KeithWailoo @statnews .@HollyLynchez; there's a lot of challenges in diversifying clinical trials but if FDA mandated it industry would figure it out. #fsp20
"The conundrum for reporters is we're presented with news we can't ignore and that we need to write about but we have to do so in a way that references the information we have but also questions the information we don't have," shares @adamfeuerstein #FSP20
We're now turning the tables a bit on @adamfeuerstein as he answers questions from our panelists @akesselheim @HollyLynchez @KeithWailoo @jasonkarlawish about reporting on FDA. #FSP20
There's still time to tune in: https://t.co/TEmeySCE4S
.@KeithWailoo - talking about the alliances that have been made between patients and patient groups and drug companies -- and how this can lead to distrust in fda due to potenital for manipulation. #fsp20
.@KeithWailoo raising an important point: "We have to highlight how politically difficult the balancing act is that FDA often finds itself in. How vulnerable to political climate these decisions can be." #FSP20
Major challenge to @US_FDA articulated by @HollyLynchez - how to incorporate patient voices in drug approval process? @US_FDA has responsibility to clearly explain their role to patients and the public to *responsibly* bring drugs to market, not just bring drugs to market. #fsp20
It's important to recognize that just following the science is not always possible: what FDA has to do is make a value judgement. They have to ask "Is there enough evidence to put this on the market or should we pull it back?" ~ @HollyLynchez #FSP20
@HollyLynchez .@HollyLynchez: Just following the science is not possible. What FDA has to do is make a value judgement about is there enough evidence informed by science but reasonable people will disagree. one way public has voice is through elections and who leads FDA. #FSP20
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.1M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.5M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
88.8M followers
Taylor Swift
@taylorswift13
82.7M followers
Lady Gaga
@ladygaga
74.2M followers
Virat Kohli
@imvkohli
71.6M followers
Kim Kardashian
@kimkardashian
70.3M followers
YouTube
@youtube
68.7M followers
Neymar Jr
@neymarjr
64.5M followers
Bill Gates
@billgates
64.5M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
61.8M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers